New BCL‑2 Inhibitor Trial in HR+ MBC – and Why Whack-a-Mole Still Matters
This trial is exciting because it is a much more direct attempt to force cancer cells into apoptosis than any standard of care ER+ therapy has attempted.
In this section
For anyone who has been offered or is considering a place in a new Phase 1 trial combining fulvestrant with a next-generation BCL‑2 inhibitor called BGB‑21447, with some trial arms also including an internal CDK4 inhibitor called BGB‑43395. https://clinicaltrials.gov/study/NCT06756932
This is an exciting trial because it is a much more direct attempt to force cancer cells into apoptosis than any standard of care ER+ therapy has attempted, but it also raises an important question: if we push harder on one anti-death pathway, what workarounds might the cancer use next?
As all my recent research summaries for the ER+ breast cancer hub shows, this question is very important. I have been encouraging readers to be thinking about three connected ideas in ER+ metastatic breast cancer: slow-growing or dormant-like cells, senescent therapy-tolerant cells, and autophagy as a survival program under endocrine and CDK4/6 pressure.
If you have not read some of what else is in this section it might help to do so. Start here: myhealingcommunity.com/breast-er
First, what BCL‑2 actually does
BCL‑2 is part of the cell’s anti-apoptosis defence system. It sits in the broader BCL‑2 family of mitochondrial “bodyguards,” whose job is to prevent the release of pro-death signals and stop the cell from going through programmed cell death.
You can think of it like this:
ER blockade removes a growth signal.
CDK4/6 inhibition slows cell-cycle entry.
But if BCL‑2 is still standing guard, the cell may not die. It may just pause, rewire, or hide.
A BCL‑2 inhibitor such as the one in this open trial BGB‑21447, is designed to directly disarm that one bodyguard. It does this by binding to BCL‑2 and preventing it from holding back the proteins that trigger mitochondrial apoptosis.
So the trial logic is very clear:
The stadard of care drug Fulvestrant takes away estrogen-driven survival signalling.
BGB‑21447 then lowers the cell’s ability to resist apoptosis.
BGB‑43395, if included, adds more cell-cycle pressure through CDK4 inhibition.
This trial provides a more targeted and harder-hitting apoptosis strategy than most supplement-based approaches.
The jury is out in terms of knowing if ‘more targeted and harder hitting’ equals more effective.
What blood cancer experience has taught us
BCL‑2 inhibitors became best known through blood cancers, especially venetoclax in chronic lymphocytic leukemia, small lymphocytic lymphoma, and acute myeloid leukemia. In those diseases, they can work very well because many cancer cells are highly dependent on BCL‑2 for survival.
But blood-cancer experience has also taught us something very important: once BCL‑2 is blocked, cancer cells often find ways around it.
The main workaround is that when BCL-2 is bound tight by the drug, other “family members” from the same anti-apoptotic family are dialed in such as:
MCL‑1
BCL‑XL
sometimes other related family supports as well.
In other words, if BCL‑2 is taken off duty, the cancer may survive by shifting its dependence to another bodyguard instead. This is one of the most common resistance themes seen with BCL‑2 inhibitors in leukemia and lymphoma, along with survival pathway rewiring through PI3K/AKT and related stress-response systems.
BCL‑2 inhibition can be powerful, but it is not automatically a full solution to the whole anti-apoptosis family.
Why this matters in ER+ breast cancer
ER+ breast cancer often expresses BCL‑2, which is one reason this trial makes biological sense. But ER+ disease can also rely on:
BCL‑XL
MCL‑1
IGF/insulin signalling
BCL-2: A New Therapeutic Target in Estrogen Receptor-Positive Breast Cancer https://www.sciencedirect.com/science/article/pii/S1535610813002821
So even if this trial drug does an excellent job at binding to BCL‑2, that does not mean the cancer has no escape routes left. It may switch bodyguards, slow down, lean harder on niche support, or use autophagy to survive the stress.
Co-inhibition of BCL-XL and MCL-1 with BCL-2 selective inhibitors A1331852 and S63845 enhances cytotoxicity of cervical cancer cell lines.
MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.
The trial is promising, but also why it fits into the wider “whack-a-mole” model for ER+ I've been honing in on.
Where autophagy fits in
Autophagy is the cell’s recycling and stress-survival system. Under treatment pressure, some ER+ breast cancer cells do not die straight away. Instead, they increase autophagy, recycle damaged material, conserve resources, and buy time.
Our recent summaries in this ER+ hub point to a pattern where endocrine pressure, CDK4/6 pressure, and therapy-induced senescence can all be accompanied by increased autophagy. That can help cancer cells stay alive long enough to become more stably resistant later.
So if we simplify it:
ER/CDK pressure can push cells into stress.
Some cells enter senescence or slow-cycling persistence.
Some use BCL‑2 family proteins to avoid apoptosis.
Some also use autophagy as a parallel survival program.
That means autophagy is not separate from the BCL‑2 story. It is one of the main alternative survival responses when apoptosis is being pressured. This hub is full of recent research summaries.
Where hydroxychloroquine comes in
Hydroxychloroquine is sometimes discussed because it can inhibit late-stage autophagy by blocking lysosomal acidification and disrupting autophagosome clearance. In simple terms, it can jam the cell’s recycling system.
That makes it interesting in a setting where the cancer may be surviving treatment stress by leaning on autophagy. The idea is not that hydroxychloroquine kills everything by itself, but that it may reduce one of the key escape programs cancer cells use when endocrine, PI3K, or apoptosis pressure is applied.
But there are important cautions:
It is not a routine add-on that should be casually layered adjunct to a Phase 1 trial.
It has its own safety issues, including eye, cardiac, GI, and interaction considerations.
In the context of a BCL‑2 inhibitor trial, it is something to ask the nurse or investigator about, not something to self-add.
So hydroxychloroquine is part of the autophagy conversation, but not automatically actionable as part of a Phase 1 trial.
What to monitor: Hydroxychloroquine is not a set-and-forget strategy.
It uses a long-half-life drug with cumulative tissue effects.
It also uses multiple compounds that converge on overlapping pathways.
Monitoring gives early warning that host burden is becoming too high.
Cardiac monitoring
Given HCQ's documented cardiotoxic potential, baseline cardiac review matters.
A baseline ECG and echocardiogram before HCQ initiation is the minimum practical starting point.
Annual ECG review during ongoing use is a reasonable floor for surveillance.
Any new conduction change, QTc issue, unexplained dyspnoea, or reduced exercise tolerance warrants immediate review.
Retinal monitoring
Baseline ophthalmology assessment also matters.
OCT macular screening is the preferred modality.
Longer-term surveillance becomes more important with cumulative exposure and higher daily dose-per-kilogram use.
How this links back to our senolytic pulse framework
In our senolytic pulse work, the idea has been that after chemo, radiation and endocrine + CDK4/6, some dangerous cells are not fully dead — they are stressed, senescent-like, slow-growing, and still salvageable unless we periodically push them further toward collapse.That framework still fits here.
The difference is:
The BCL‑2 inhibitor trial drug is more targeted and stronger at one anti-apoptosis node, BCL‑2.
The senolytic pulse is broader and less precise, potentially leaning across a wider set of anti-apoptotic and pro-survival programs, including parts of the BCL‑2 family, inflammatory signalling, metabolic stress pathways, and possibly some senescent-cell dependencies.
So the comparison is not “drug good, pulse bad” or vice versa.
It is more like:
Trial drug: sharper and more potent, but narrower.
Senolytic pulse: broader and more whole-network but perhaps less pharmacologically exact.
For people unable to access the trial drug adding the senolytic pulse may be still well suited especially given the way it meets the full anti-apoptosis family problem.
See the senescence page to learn more.
Where EGCG, curcumin, and berberine fit now
In the reflections shared regarding the Slow-Growing-ER-Breast-Cancer-Cells- study summary (again ER+ hub's overview page will have a link) a day-to-day framework was shared. It pointed to liposomal EGCG, liposomal curcumin, and liposomal berberine for applying background pathway pressure against some of the common escape routes:
insulin / IGF signalling
NF‑κB and inflammatory signalling
PI3K/AKT/mTOR crosstalk
some anti-apoptotic outputs
and some metabolic flexibility that helps resistant cells survive.
Then on top of the day to day the senolytic pulse every 3–4 weeks is intended as the more forceful periodic attempt to target the anti-apoptosis body guard family and clear out the stressed, senescent-like, and therapy-tolerant cells.
This still remains a coherent framework for community education. But for someone inside a Phase 1 trial, these are not things to simply continue automatically.
The EGCG, curcumin, berberine, fisetin, quercetin, apigenin and hydroxychloroquine are all scientifically relevant to escape-route thinking, but they must be cleared with the trial nurse or investigator before use, because Phase 1 trials need transparent safety and drug-interactions discussed.
The takeaway
This trial is exciting because it directly targets one of the major anti-apoptosis locks in ER+ metastatic breast cancer. But it also reminds us of something our recent summaries have been circling around all along:
Cancer rarely relies on only one survival trick.
When you pressure ER, it may lean on CDK and IGF.
When you press down on CDK, it may slow down and become senescent-like.
When you pressure apoptosis through BCL‑2, it may result in upregualting MCL‑1, BCL‑XL, and/or autophagy.
When you pressure one route hard enough, the tumour may survive by shifting state rather than by brute growth.
That is why the “whole-network” view still matters.
For those interested in the BCL-2 trial.
The BCL‑2 inhibitor trial is likely to be a much more direct and potent apoptosis trigger than nutraceutical senolytic strategies. But it does not automatically shut down autophagy, MCL‑1, BCL‑XL, or all of the other ways ER+ cells survive treatment stress.
So the best next step is not to self-layer extras alongside the trial. It is to ask the trial team clearly about:
EGCG
Curcumin
Berberine
Hydroxychloroquine
Fisetin
Quercetin
Apigenin (about to be added to the pulse stack)
Unpacking Timing of Each of the “Extras”
In preparation for a conversation with the trial nurse or investigator, it is worth going one level deeper than “is X allowed?” and thinking in terms of pharmacokinetics, metabolism, and timing for each of these Extras. The practical questions are:
At what dose and schedule would an agent like curcumin, EGCG, berberine, fisetin, quercetin, apigenin or hydroxychloroquine be pharmacologically meaningful?
At what point does the dose or timing start to create real interaction or safety concerns with the BCL‑2 inhibitor, fulvestrant, and (if used) the trial CDK4 inhibitor?
If the trial team only permits a very low dose or a long separation (for example, “a standard curcumin capsule 6 hours after study drug”), is that enough to justify using it, or is it more honest to say “probably not doing much” and park it for later?
This leads naturally to a strategic fork:
On‑trial phase:
The priority is to let the BCL‑2 inhibitor and fulvestrant (± BGB‑43395) do their work with clear safety and PK visibility.
Any allowed supplements are likely to be at low, conservative doses with wide time separation from study dosing.
In that context, they may still be useful for general terrain (e.g. mild anti‑inflammatory, immune or bone support), but they are unlikely to be acting as full‑strength pathway‑targeting tools.
Post‑trial / between‑line phase:
If or when the trial stops working, this is when a participant may actually want maximal freedom to roll out a stronger, liposomal, higher‑dose senolytic/anti‑escape and autophagy targeting strategy.
At that point there is no need to protect trial integrity, and the goal shifts from “do not confound Phase 1 data and risk harm to oneself” to “salvage and re‑shape the terrain as much as possible.”
Seen this way, a very reasonable plan for someone in this situation could be:
During the trial:
Use only what the protocol clearly allows, at doses and timings agreed with the nurse/PI.
Accept that some favourite agents will either be paused or used in low rather than optimal doses, and that this is part of participating in early‑phase research.
Keep a stock of desired agents (EGCG, curcumin, berberine, fisetin, quercetin, apigenin, hydroxychloroquine) plus target doses and rationale ready for rapid deployment if/when the study period ends.
After the trial or if progression occurs:
Re‑introduce or escalate the Extras in a more meaningful way: liposomal formulations, doses closer to those used in preclinical or pilot‑clinical work, and schedules that line up with senolytic pulses and endocrine/CDK strategies rather than with Phase 1 constraints.
At that point, think of the BCL‑2 inhibitor as having done a “proof‑of‑concept hit” on one lock, and your senolytic/autophagy stack as the follow‑on attempt to cover the rest of the family too, and pathways that stepped up during the trial.
So the key reflection is:
If a trial only allows a tiny token dose of a complex nutraceutical, it may be more honest to treat that as simply supportive terrain care rather than as a serious pathway‑targeting tool. The real opportunity to use these compounds at effective doses may actually be after the trial, when the next wave of bodyguards is visible and you are free to hit them without Phase 1 restrictions.
Framed this way, the conversation with the trial team becomes less “Can I sneak my protocol in around the edges?” and more
“What is safe and meaningful to do during the trial, and what protocols should I deliberately prepare for and have on hand for immediate use post‑trial phase when drug has done what it can and I need to pick up from there- fast?
Return to the A–Z directory of
evidence-based research summaries and
practical support resources